The Asia Pacific patient controlled injectors market is expected to reach US$ 1,637.74 million by 2027 from US$ 621.47 million in 2019; it is expected to grow at a CAGR of 12.9% from 2020 to 2027.
The increasing prevalence of chronic diseases and limitations on conventional drug delivery system boost the growth of the market. However, the lack of adoption of patient controlled injectors in emerging countries restrains the growth of the market. Technological advancements and design development, and patient controlled injector industries consolidation are likely to fuel the growth of the Asia Pacific patient controlled injectors market during the forecast period.
Patient controlled Injectors are subcutaneous drug delivery systems that adhere to the body and administer larger volumes (more than 2 mL) of a drug over an extended period. With the use of patient controlled injectors, dosing errors, microbial contamination risks, and needle stick injuries can be avoided that are caused during parenteral drug administration using injections. In the last few years, the pharmaceutical industry has witnessed the introduction of several innovative interventions for the treatment of various chronic diseases. However, the majority of the available treatments require parenteral drug administration, frequent dosing, and repeated hospital visits. Therefore, patient controlled injectors are preferred for the treatment of chronic diseases where long-term treatment is necessary. Chronic diseases, such as blood disorder, autoimmune disorders, and various types of cancer, are the leading causes of death and disability.
Cardiovascular diseases (CVDs) are a significant cause of mortality owing to the hectic lifestyle. The Global Burden of Disease study estimates that the age-standardized CVD death rate is 272 per 100,000 people in India that is higher than the global average rate, which is 235 per 100,000 people. Premature mortality in terms of years of life lost because of CVD in India increased by 59%. Many biologics are commercially available for the treatment, but the conventional drug delivery methods are unable to provide accurate dosage. In this case, the use of patient controlled injector drug delivery systems plays vital role to provide targeted drug delivery and prolonged drug residence to the affected areas of the cardiovascular system. Hence, the adoption of patient controlled injectors is likely to increase.
Asia Pacific countries are witnessing massive challenges due to the COVID-19 outbreak as overall economic conditions and healthcare industries are adversely affected. Prohibitory measures have been taken to control the spread of the novel coronavirus. However, hospitals, clinics, diagnostic centers, and ambulatory surgery centers (ASCs) are not taking general patients on priority. Therefore, patient controlled injectors market in Asia Pacific is also facing challenges due to the outbreak.
In 2019, the electronic injector segment accounted for the largest market share of the Asia Pacific patient controlled injectors market. Electronic injector offers various benefits such as comfort, water resistance, flexible dosing, and automatic warming of refrigerated drug as well as it is easy to use. These benefits accelerate the demand for electronic injector. A mechanical injector eliminates the risks of skin fitting issues and allergic skin reactions; therefore, the market for mechanical injector segment is expected to grow at a faster pace during the forecast period.
A few of the major secondary sources referred to while preparing this report on the Asia Pacific patient controlled injectors market report are World Health Organization (WHO), Global Burden of Disease (GBD), Indian Council for Medical Research (ICMR), Institute for Health Metrics and Evaluation, International Diabetes Federation (IDF), Australian Bureau of Statistics, Health Ministry of Japan and others.